Scarica l'app Stockscreener
1.685
10.85%
-0.205
Dopo l'orario di chiusura:
1.75
0.065
+3.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.89
Aprire:
$1.88
Volume 24 ore:
562.79K
Relative Volume:
3.04
Capitalizzazione di mercato:
$20.61M
Reddito:
-
Utile/perdita netta:
$-16.76M
Rapporto P/E:
-21.06
EPS:
-0.08
Flusso di cassa netto:
$-132.97M
1 W Prestazione:
-11.32%
1M Prestazione:
-60.81%
6M Prestazione:
-92.00%
1 anno Prestazione:
-89.77%
Intervallo 1D:
$1.68
$1.93
Intervallo di 1 settimana:
$1.68
$2.12
Portata 52W:
$1.68
$26.96
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Nome
X 4 Pharmaceuticals Inc
Settore
Industria
Telefono
857-529-8300
Indirizzo
61 NORTH BEACON STREET, BOSTON, MA
Confronta XFOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
1.685 | 20.61M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-12 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Ripresa | B. Riley Securities | Buy |
| 2022-12-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | ROTH Capital | Buy |
| 2019-12-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-12-05 | Iniziato | B. Riley FBR | Buy |
| 2019-06-07 | Iniziato | Stifel | Buy |
| 2019-06-05 | Iniziato | Cowen | Outperform |
Mostra tutto
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 27.1% in May - Defense World
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association - MarketScreener
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
XFOR Presents Positive Phase 2 Trial Results for Mavorixafor at EHA Congress | XFOR Stock News - GuruFocus
X4 Pharmaceuticals presents positive data from neutropenia trial By Investing.com - Investing.com Canada
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - marketscreener.com
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Brokers Offer Predictions for XFOR FY2026 Earnings - Defense World
X4 Pharmaceuticals Elects New Director at Annual Meeting - TipRanks
X4 Pharmaceuticals Grants Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - marketscreener.com
X4 Pharmaceuticals Granted Fast Track Designation For Mavorixafor For Treatment Of Chronic Neutropenia By US FDA - MarketScreener
X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia - MSN
X4 Pharmaceuticals (XFOR) Gains FDA Fast Track Status for Mavorixafor | XFOR Stock News - GuruFocus
FDA grants fast track status to X4’s neutropenia drug - Investing.com
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - Quantisnow
Stock split by pharma company: Record date this week; Rs 297 crore order windetails - ET Now
Director Dugan Richard W was granted 59,225 shares, increasing direct ownership by 50% to 177,454 units (SEC Form 4) - Quantisnow
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - Insider Monkey
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XFOR Stock News - GuruFocus
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump - simplywall.st
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - AOL.com
Top 10 pharma companies in India by market cap [2025] - Forbes India
Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewswire
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4% – Here’s Why - Defense World
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares - Yahoo Finance
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times
Bankrupt 23andMe Expected to Be Purchased for $256M - People.com
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - Quantisnow
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Waters Corp's India business boosted by rush for weight-loss drugs - Reuters
X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress - marketscreener.com
X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
X 4 Pharmaceuticals Inc Azioni (XFOR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
1.08%
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):